Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ French Markets Regulator Orders Vivendi Withdrawal Offer (Bloomberg) +++ VIVENDI Aktie +4,00%

INTELLIA Aktie

 >INTELLIA Aktienkurs 
10.105 EUR    -0.9%    (Tradegate)
Ask: 10.455 EUR / 582 Stück
Bid: 10.205 EUR / 590 Stück
Tagesumsatz: 533 Stück
Realtime Kurs von 8 bis 22 Uhr!
INTELLIA Aktie über LYNX handeln
>INTELLIA Performance
1 Woche: +0,5%
1 Monat: +24,1%
3 Monate: +66,4%
6 Monate: +11,6%
1 Jahr: -58,7%
laufendes Jahr: -8,5%
>INTELLIA Aktie
Name:  INTELLIA THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45826J1051 / A2AG6H
Symbol/ Ticker:  38I (Frankfurt) / NTLA (NASDAQ)
Kürzel:  FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA
Index:  -
Webseite:  https://www.intelliatx.co..
Marktkapitalisierung:  751.56 Mio. EUR
Umsatz:  39.45 Mio. EUR
EBITDA:  -459.56 Mio. EUR
Gewinn je Aktie:  -3.931 EUR
Schulden:  103.25 Mio. EUR
Liquide Mittel:  436.14 Mio. EUR
Umsatz-/ Gewinnwachstum:  -42.5% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  19.1 / 1.15 / -
Gewinnm./ Eigenkapitalr.:  - / -57.92%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 64.009 USD.
Suchwörter:  INTELLIA
Letzte Datenerhebung:  18.07.25
>INTELLIA Eigentümer
Aktien: 103.58 Mio. St.
f.h. Aktien: 98.47 Mio. St.
Insider Eigner: 4.96%
Instit. Eigner: 97.2%
>INTELLIA Peer Group

 
07.07.25 - 22:03
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment....
07.07.25 - 17:30
Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
 
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention....
04.07.25 - 02:01
Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 10036 USD (Insiderkauf)
 
Clark, Eliana - Vorstand - Tag der Transaktion: 2025-07-01...
04.07.25 - 02:01
Insiderhandel: VP, Chief Accounting Officer verkauft Aktien von Intellia Therapeutics im Wert von 24905 USD (Insiderkauf)
 
Dube, Michael P. - Vorstand - Tag der Transaktion: 2025-07-02...
03.07.25 - 02:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Intellia Therapeutics im Wert von 14789 USD (Insiderkauf)
 
Goodman, Jesse - Aufsichtsrat - Tag der Transaktion: 2025-06-30...
03.07.25 - 02:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Intellia Therapeutics im Wert von 14279 USD (Insiderkauf)
 
Goodman, Jesse - Aufsichtsrat - Tag der Transaktion: 2025-07-01...
25.06.25 - 17:30
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
 
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains....
15.06.25 - 16:48
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom....
05.06.25 - 22:06
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment....
04.06.25 - 17:30
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% (Zacks)
 
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....
30.05.25 - 18:15
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks)
 
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation....
29.05.25 - 17:54
Intellia Plunges in Latest Example of Gene Therapy Troubles (Bloomberg)
 
Intellia Therapeutics Inc. fell Thursday after disclosing a patient experienced a severe side effect from its gene-editing treatment for a heart condition, the latest safety issue tied to DNA-targeting therapy....
29.05.25 - 14:36
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews (Benzinga)
 
Latest Ratings for NTLA DateFirmActionFromTo Mar 2022Brookline CapitalUpgradesHoldBuy Mar 2022Chardan CapitalMaintainsBuy Feb 2022William BlairInitiates Coverage OnOutperform View More Analyst Ratings for NTLA View the Latest Analyst Ratings read more...
29.05.25 - 13:57
Intellia stock tumbles on safety concerns (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
29.05.25 - 13:36
Intellia slides after safety concern for Regeneron-partnered gene editing therapy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.05.25 - 16:45
3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
 
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV)....
18.05.25 - 13:27
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting (GlobeNewswire EN)
 
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation....
15.05.25 - 17:30
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? (Zacks)
 
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
09.05.25 - 19:45
Intellia′s Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
 
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise....
08.05.25 - 17:45
Intellia therapeutics outlines 2026 BLA filing for NTLA-2002 in HAE amid strong Phase 3 progress (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der König der Flöhe ist in Tiberias. - D. h., das Schlechte mag eine ganz andere Ursache haben als man vermutet. - Sprichwort Arabisch
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!